Ke kinipona lipantil: nā ʻōlelo no ka hoʻohana ʻana

i loko o kahi pōkole 10 pcs., i loko o kahi pākeke o nā pololi 3.

Lapaʻau lāʻau

Pākuʻi ʻia nā triglycerides a me ka liʻiliʻi, ʻo ka kolamu ma ke koko. Kōkua ia i ka hōʻemi i nā kiko'ī o VLDL, i kahi haʻahaʻa - LDL, hoʻonui i nā ʻike o ka antiL atherogen HDL. Hoʻoulu ia i ka lipoprotein lipase a, no laila, pili i ka hoʻonaninohi o nā triglycerides, hoʻonāukiuki i ka paʻi ʻana o nā momona momona a me ka cholesterol, a kōkua i kahi hoʻonui ʻana i ka nui o nā meaʻai LDL i loko o ka ate. Hoʻopau ka Fenofibrate i ka hoʻoneʻe ʻana o ka platelet, hoʻemi i ka nui o ka plasma fibrinogen kiʻekiʻe, hiki ke hoʻohaʻahaʻa i ka pae o ka glucose koko i nā maʻi me ka maʻi mellitus, a hoʻemi i ka pae o ka wa uric acid i ke koko.

Lapaʻau lāʻau

ʻO ka metabolite nui ka acid acidofibroic. Ma hope o ka lawe ʻana i ka lāʻau lapaʻau ma loko C_max i loko o ka plasma i hōʻea ma hope o nā hola he 5. I ka manawa i lawe ai ma kahi o 200 mg o ka mika, ke kōʻai nui o ka plasma he 15 μg / ml. Noho ka plasma o ka lāʻau lapaʻau. T_1/2 fenofibroic acid - ma kahi o nā hola 20 he excreted nui loa i ka urine (fenofibroic acid a me kona glucuronide) ma hope o 6 mau lā. ʻAʻole i hōʻiliʻili ia i ka wā e lawe ai i kahi pākahi hoʻokahi a me ka hoʻohana lōʻihi. ʻAʻole i hoʻopili ʻia ka waikele Fenofibroic i ka wā o hemodialysis.

Nā Hoʻohui

Ka hopena o ka hōʻeha o ka ate a me ka hana ʻana, ka mōʻaukala o ka hopena phototoxic a photoallergic i ka wā o ka mālama ʻana me ka fenofibrates a i nā lāʻau like ʻole e like me ke ʻano like, like ketoprofen, hui pū me nā fibrates, nā keiki ma lalo o ka 18 mau makahiki o ka umauma, hapai, lactation, galactosemia congenital, ʻeha lactase.

Nā hopena hopena

E hoʻokaʻawale i ka myalgia, ka ʻehaʻeha o ka ʻōpū, nā nāwaliwali, a (ma nā hihia lohi) rhabdomyolysis, i kekahi manawa he paʻakikī. Ke hoʻokuʻu ʻole ʻia ka mālama ʻana, ʻike pinepine kēia mau ʻano.

Mai ka palaki kuʻekuʻe: ʻĀpepsia. ʻO ka hana e hoʻonui ai i nā transaminases hepatic i serum.

Nā maʻi kūwaha: kuaʻu - rashes ʻili, itching, urticaria, photosensitivity. I kekahi mau hanana (ma hope o kekahi mau mahina o ka hoʻohana ʻana), e ulu ka mea photosensitivity i ke ʻano o ka erythema, papules, vesicles, a i ʻole eczematous rashes.

Hoʻohui

Nā hui i hoʻohālikelike ʻia: me nā fibrates ʻē aʻe, he hoʻonui nui aʻe o nā ʻaoʻao ʻaoʻao (hōʻeha kino).

Hoʻohui like ʻole: me ka HMG-CoA reductase inhibitors - ʻoi aku ka nui o ka loaʻa ʻana o ka hopena ʻokoʻa (hōʻeha kino ʻana).

Hoʻohana ʻia nā hui me ka mālama - me nā kūlohelohe kūwaho (kū i ke kahe koko). ʻOi aku ka ʻike pinepine o ka PV i ka wā e koho ai i kahi pāʻina o ka anticoagulant kūhelu i ka wā o ka mālama ʻana me nā fibrates a i loko o 8 mau lā ma hope o ko lākou haʻalele.

ʻAʻole hoʻohana ʻia ʻo Fenofibrate me ka pale me MAO inhibitors.

ʻO nā mea mālama palekana

Aia nā hopena o ka hopena o nā fibrates ma ka pūpū o ka ʻiʻo, me nā hihia līpona i loaʻa ʻole i ka necrosis. Hōʻike pinepineʻia kēia mau kaʻina me ka hoʻoneʻe liʻiliʻi o ka plasma albumin. Pono e mālama ʻia ka hopena i hōʻike ʻia i nā maʻi āpau me ka wehe ʻana i ka myalgia, me ka ʻehaʻeha o nā iwi a me kahi piʻi nui o ka pae o ka phosphokinase (5 mau manawa i kiʻekiʻe aʻe ma mua o ka maʻamau) I kēia mau hihia, pono e hoʻokaʻa ʻia ka mālama ʻana.

Eia kekahi, hiki ke hoʻonui ʻia ka pilikia o ka hōʻeha o ka hoʻi ʻia inā ke kauoha ʻia ka lāʻau me nā HMG-CoA reductase inhibitors.

Ma muli o ka heleʻana o ka lactose, ua contraindicated ke kinipiko i ka galactosemia congenital, ma ka hopena o ka glucose a me ka galactose malabsorption syndrome a i ʻole i ka hopena o ka nele o ka lactase.

Inā ʻaʻole i loaʻa ka hoʻoluʻu maikaʻi ʻana i nā lipine serum i ka wā o ka hoʻohana ʻana i ka lāʻau no 3-6 mau mahina, pono e hāʻawi ʻia kahi ʻano therapeutic ʻokoʻa.

Pono ka nānā ʻana o kahi mākaukau o ka pae o ka transaminases hepatic i loko o ka serum koko i kēlā me kēia 3 mau mahina ma ke mau mahina 12 mua o ka mālama ʻana he pono. Inā hoʻonui ʻia ka pae o AST a me ka ALT e ʻoi aku ma mua o 3 mau manawa i hoʻohālikelike ʻia me VGN, pono e hoʻokaʻawale ke ʻano.

Ke hoʻohui pū ʻia me nā anticoagulants kūlike, pono ka makaʻala e pili ana i ka ʻōnaehana koikoi koko.

Ka hana lāʻau lapaʻau

Aia ka maʻi Hypolipidemic, he hopena uricosuric a me ka antiplatelet. Hoʻemi i ka kolamu koko nui ma 20-25%, koko TG e 40-45% a me ka uricemia e 25%. Me ka hoʻomehana paʻa mau, hoʻemi ʻia ka nui o nā kolikoli extravascular.

Hoʻēmi i ka hoʻoneʻe ʻana o TG, VLDL, LDL (i kahi ʻokoʻa liʻiliʻi), hoʻonui - HDL, hoʻonāukiuki i ka hoʻāʻo ʻana o ka waika momona. Hoʻēmi i ka hoʻohui platelet, e hōʻemi ana i ka kiʻekiʻe plasma fibrinogen. I ka poʻe maʻi me ka maʻi maʻi maʻi i kekahi hopena hypoglycemic.

Nā ʻōlelo kikoʻī

Pono e hoʻokololei ʻia ka lāʻau lapaʻau me ka hoʻākina o ka papa kolamu a ma lalo o ka mākaʻi o kekahi kauka.

I ka loaʻa ʻole o kahi hopena kūpono ma hope o 3-6 mau mahina o ka hoʻokele, hiki ke kuhikuhi ʻia i ka concomitant a i ʻole kekahi ʻano lapaʻau.

Manaʻo ʻia e nānā i ka hana o ka "hepatic" transaminases i kēlā me kēia 3 mau mahina ma ka makahiki mua o ka papa lapaʻau, he hoʻomaha iki no ka mālama ʻana inā e hoʻonui ʻia kā lākou hana, a wehe ʻia mai ka pili like o nā lāʻau hepatotoxic.

Hoʻomili hou a me ke ʻano hoʻohālikelike

ʻO ka lāʻau Lipantil 200 m nona ka hua lāʻau lapaʻau o nā huahana waikawa fibroic. ʻO ka mea hana nui ka fenofibrate. Hoʻopiʻi ia i nā mea nānā PPA-α, hoʻopōmaikaʻi i ka hana a nā lipase lipoprotein. Hoʻolaha kēia kaʻina hana i ke kaʻina o ka hoʻokaʻawale i ka momona a me ka weheʻana i nā kikoʻi triglyceride mai ke koko. No laila, ʻo ka pae o ka lipoproteins haʻahaʻa haʻahaʻa e hoʻololi me ka hoʻololi ʻole, a me ka nui o nā lipoproteins kiʻekiʻe, ke ʻole, e hoʻonui aʻe. ʻO ka Fibrate me ka pane ʻole i ka hoʻokahe koko koko. E kōkua ana ka lāʻau lapaʻau e hoʻolaʻa i ka nui o nā fibrinogen, e pale ai i ka hoʻokumu ʻana o nā māka koko.

ʻO ka hoʻokuʻu ʻana o ka Lipantil ka pahu gelatin brownish paʻakikī i loaʻa i kahi pau i ke keʻokeʻo ma loko. Loaʻa ka lāʻau lapaʻau i kahi kaona o 200 mg, 30 mau ʻāpana no ka pā. ʻO ka'āina mai - Farani. Hiki iā ʻoe ke kūʻai i ka lāʻau ma o ke kau lama lā.

Nā hōʻailona no ka hoʻohana ʻana

Ka hiolo ʻana o ka kolamu o ka mua a me ka papa ʻelua ma muli o Fredrickson ka hōʻailona kumu no ka koho ʻana iā Lipantil. Me ka hyperlipidemia hui pū ʻia, pono ia e hoʻopili i nā papa o Lipantil i ka hoʻolālā therapeutic. Pono koi hoʻi ka triglycerides i ka fenofibrate. ʻO ka holomua o ka atherosclerosis ka piʻi ʻana o ka hoʻoulu a me nā kīwaha myocardial. Ma kēia mea, no ke pale ʻana, ʻōlelo aku nā kauka iā Lipantil.

Me ka hoʻomau ʻole ʻia me nā lāʻau ʻē aʻe hypolipidemic, no ka laʻana, statins, hoʻohana ʻia ka hoʻohana fenofibrate e like me kahi mea hou aku.

Nā hopena hopena

ʻO ka pinepine, ʻōhumu nā poʻe maʻi i nā ʻāpana pale. I kekahi manawa hiki ke hōʻeha ka ʻeha o ka naʻau, ma ka hihia maikaʻi loa, ʻo ka luku ʻia ʻana o nā uaua o ka ʻiʻo. ʻIke ʻia nā hua maʻi hypersensitivity i nā ʻāpana pilikino o Lipantil. Lahi paha ka ʻūhā a me ka ʻeha. E like me ka hapa nui o ka lipid-haʻahaʻa, hoʻōla ka fenofibrate i ka pae o nā enzyme o ke aʻai i loko o ke koko. Ma hope o ka pau ʻana o ka papa o ka mālama ʻana, a nalo pinepine nā ʻaoʻao.

I nā hihia ʻē aʻe o ka overdose, hana ʻia ke ʻano hōʻailona maʻi.

ʻLoe a me ke kākele

Hiki ke koho ʻia ka maʻi kūpono ʻana e kāu kauka, me ka noʻonoʻo ʻana i ka mōʻaukala pilikino. ʻO ka dosage maʻamau ʻo 200 mg o ka lāʻau i ka lā. Ma ke ʻano o ke kauka, i kekahi manawa i ka ʻāpana o ka lā i hoʻokaʻawale ʻia i ʻekolu mau pona. Lawe ʻia ka pāpana me ka meaʻai, holoi ʻia me ka wai. Ma nā ala ākea nui, hiki i ka lā maʻamau no ka lāʻau lapaʻau a hiki i 400 mg. I kēia hihia, aia ka mea maʻi ma lalo o ka mālama kiaʻi o nā limahana olakino.

Nā hiʻohiʻona noi

Mai hoʻohana i kahi huahana lapaʻau no ka malabsorption o ka glucose, galactose. I ke kuhikuhi ʻana i nā derivatives o ka fibroic acid, pono e hoʻoponopono pono i nā ʻōnaehana transaminases. Nā mea koikoi coagulation kūloko me ke nānā mau ʻana. ʻAʻohe hihia e hiki ke hoʻohui i ka hoʻokaʻawale a me nā waiʻona. Hiki i kēlā hui pūpū ke loaʻa i ka hopena i nā leʻaleʻa i nā pona o ke ake, i nā hihia maikaʻi loa, me nā hopena hiki ʻole.

I ka wā hāpai a me ka lactation

ʻO ka wā o ka hapai ka haʻalele i ka hoʻohana ʻana i nā lāʻau lapaʻau. ʻOiai, e like me ka hana umauma. ʻOiai mai ka waiū hānai, hiki i ka lāʻau lapaʻau ke hoʻopilikia i ka pēpē.

ʻAʻohe ʻike data noiʻi e pili ana i ka hopena o nā lāʻau lapaʻau ma ke kino o nā keiki. Ma kēia mea, cont conticated i nā keiki.

Ka lāʻau kūʻai lāʻau

Fenofibrate, inoa inoa ʻo Lipantil 200 M, ma Ukraine e hiki ke kūʻai ʻia ma ke kumu kūʻai ma o 520 UAH no 30 mau papa. I loko o nā lāʻauʻai o ka Russian Federation, e kūʻai ka lāʻau lapaʻau iā ʻoe ma kahi o 920 mau rubles no kahi pōʻai like. Mai poina e hōʻike i kāu lāʻau lapaʻau i kahi papa lāʻau mai kahi kauka ma mua o ke kūʻai. Hōʻike e hōʻoia inā ua pau ka lāʻau.

Nā kikowaena Lipantil

Inā kiʻekiʻe loa ka nui o nā dosis o Lipantil no ka mea maʻi, hoʻowalewale ʻia me kahi haʻahaʻa o nā fibrate haʻahaʻa. No ka laʻana, Tricor, i paʻi ʻia ma kahi pāʻālua o 145 mg i hoʻokahi papa i ka mea kanu like me Lipantil. Loaʻa nā kuleana'ē aʻe o ka waihona kālā no Fenofibrat Canon, mea i hana ʻia e Lūkia, a me Exlip, Turkey. ʻO kāu kauka wale nō e kōkua i ka hoʻomaopopo hope loa i ka nui o nā mea hoʻohana i ka lāʻau lapaʻau e kūʻē i ka kolamu. ʻAʻole alakaʻi e ka ʻōlelo ʻike mai ka Pūnaewele.

Nā Hōʻike Hoʻohana

ʻO nā ʻōlelo a nā kauka e pili ana i ka lāʻau lapaʻau ke maopopo leʻa - ʻike ʻia ka hopena maikaʻi. I ka mahina mua o ka lāʻau lapaʻau, hiki iā ia ke loiloi i ka hopena mua a, inā pono, hoʻoponopono i ke ʻano. Hiki i ke lipantil ke lilo i monotherapy, i hui pū ʻia me nā lāʻau lapaʻau ʻē aʻe.

ʻO nā mea maʻi ke nānā nui loa i ka hopena o ka lāʻau lapaʻau ma ka ate. Akā ʻo kahi hōʻemi pono ʻana i ka cholesterol ka hoʻopiʻi piha ʻana i ka hopena o nā hopena ʻaoʻao. Kuhi ka poʻe nui i ka hopena maikaʻi ʻole o ka lawe ʻana i nā paila e hiki ke ʻae a hoʻopau ʻia. A ʻo kaʻoiaʻiʻo, ʻaʻole kūpono ke kumukūʻai no nā poʻe āpau. Akā, ʻike ka poʻe he nui ka huahana kūpono a me ka laikini ua lawa ʻia nā kālā.

Pākuʻi helu

Aia i hoʻokahi kapsul

mea waiwai - micronized fenofibrate 200 mg,

nā mea waiwai: lactose, sodium lauryl sulfate, st prelelatinized starch, crospovidone, magnesium stearate,

mau pūpū papa: titanium dioxide (E 171), Iron (III) oxide yellow E172, Iron (III) oxide red E172, gelatin.

Okaque capsules kukui brown No. 1. ʻO nā mea o nā kāpili he keʻokeʻo a ʻokoʻa paha ke keʻokeʻo keʻokeʻo

ʻO ke kūpaʻa overdose a me nā lāʻau lapaʻau

Ma ka hoʻomaʻamaʻa kulekele, ʻoi aku ka loaʻa ʻana o ke ʻano maʻi meʻa. Hōʻike ʻia kahi overdose o Lipantil e ka hiamoe, ke kuhi ʻana, ka hoʻomaloʻo, nā lua o ka digestive. E koi ʻia ka nui o Gastric, i ukali ʻia e ka intake o kekahi enterosorbent - carbon activated, Smecta, Enterosgel. Pono e ʻimi koke i ke kōkua olakino no ka detoxification a me ka mālama maʻi.

Hoʻonui maoli ka hopena hypoglycemic i ka lāʻau lapaʻau me ka derivatives sulfonylurea me kā lākou hoʻohana pinepine ʻana me Lipantil. Hoʻonui pū ia i ka pono o ka therapeutic efficulates o nā coagulants kūlike, ʻaʻole e aʻo mau ʻia. ʻO ka hui pū ʻana o ka cyclosporine a me kahi lipid-hoʻohaʻahaʻa i hoʻonāukiuki i ka hōʻemi ʻana o ka hana hana o nā ʻāpana urinary, ʻo ia hoʻi nā māla.

Hoʻohui ʻia ka hui ʻana ma nā therapeutic schemes o Lipantil me kekahi lāʻau lapaʻau mai ka statin pūʻulu inā hiki ke hōʻeha ʻia ka dyslipidemia i hoʻopilikia ʻia me kahi puʻuwai cardiovascular kiʻekiʻe, ma kahi o ka mōʻaukala o nā degenerative pathologies. Pono e mālama ʻia ka hoʻomaʻamaʻa ʻana i nā kūlana o ka mālama mālama olakino e kuhikuhi ana i ka ʻike ʻana i nā hōʻailona o ka hana ʻino o nā uaua ʻāwili.

Nā hōʻike a me ke kumukūʻai

Ua kuhikuhi ka poʻe Cardiologists i nā analoge Lipantil me ka hoʻomehana ʻana o kēlā me kēia wai. Ke lawe ʻia nei ka loli me ka haʻahaʻa haʻahaʻa o kāna hoʻohana ʻana no kekahi mau mahina, kahi emi ʻole i ka pae o ka triglycerides a me nā lipoproteins haʻahaʻa haʻahaʻa i loko o ka ʻōnaehana ʻōnaehana.

ʻO ka hana e hoʻohana ana i nā lāʻau lapaʻau me ka hiki ke kiʻekiʻe i ka hoʻohemo ʻana i nā koloka a hoʻopau iā lākou mai ke kino. I nā hōʻailona kikoʻī o Lipantil, ʻōlelo pinepine ʻia ʻo Fenofibrate. ʻO Clofibrate a me gemfibrozil kahi hana hoʻomehana like.

He ʻano ʻē aʻe ka kumukūʻai o Lipantil ma nā wahi like ʻole o ka ʻāina. Ma Moscow, hiki ke kūʻai ʻia i kahi papa o nā papa No 30 i kahi maʻa o 200 mg no nā 780 rubles. Ma Nizhny Novgorod aia he 800 rubles, a ma Volgograd kona kumukūʻai ʻo 820 mau rubles.

Ke hoʻoholo nei i ka koho ʻana i kahi lāʻau maikaʻi maikaʻi a kiʻekiʻe maikaʻi e hōʻemi i ke kiʻekiʻe o ka triglycerides i ke kahe koko e maʻalahi nā mea maʻalahi. Ma nā pūnaewele lāʻau olakino a me nā lāʻau lapaʻau he nui nā loiloi kūpono e pili ana iā Lipantil. Wahi a nā mea maʻi Cardiologist ua kāpae ka lāʻau lapaʻau i nā hōʻailona āpau o ka hyperlipidemia i loko o 2-3 mau mahina. Hoʻomaopopo lākou i ka palekana o ka lāʻau lapaʻau, kahi hōʻike maʻamau o nā hopena ʻali a kūloko a me nā ʻōnaehana.

ʻO Maria Dmitrievna, 64 makahiki, Ryazan: ua hoʻomaka koʻu pae kolamu mai ka 50 makahiki. I ka wā mua, ʻaʻohe ʻano hōʻailona, ​​akā ʻoi ke ʻano o kona ola kino. Ua hoʻomaka koʻu poʻo i ke kaumaha, pōkole o ka hanu ua hele mai a me nā hele wāwae pōkole. Ua kuhikuhi ka cardiologist e lawe i nā kapena Lipantil no ʻekolu mau mahina. Hoʻomaka ka olakino e hoʻomaikaʻi ma kahi o hoʻokahi mahina.

Nikolay, 49 makahiki, Zheleznovodsk: I loaʻa iaʻu kahi predisposition hoʻoilina i ka hoʻomohala ʻana o ka maʻi puʻukui coronary. No laila, ua kuhikuhi ʻo ka cardiologist i nā hana ma hope koke o ka nānā ʻana i kahi kiʻekiʻe o ka triglycerides. I ka wā mua ua lawe au i nā lāʻau lapaʻau mai ka pūʻulu statin, akā ʻoi aku ka maikaʻi o ka hopena ma mua o ka mea i manaʻo ʻia. Ua ʻōlelo aku ke kauka ke lawe ʻana i Lipantil ma kahi o 200 mg o. Ekolu mahina ma hope mai, maikaʻi loa nā hōʻike biochemical.

ʻO nā waiwai Pharmacological

Kapehu. Ma hope o ka hoʻokō ʻana o ka waha o ka lipantil 200M Cmax capsule (ka nui loa o ka ʻā) o ka acid fenofibroic i loaʻa ma hope o nā hola 4-5. Me ka hoʻohana mau ʻana, hoʻomau mau ke kuhi o ka waikawa fenofibroic i loko o ka plasma, e like me ka mea o nā kūʻokoʻa o ka mea maʻi. Cmax i loko o ke koko koko a me ka hopena o ka fenofibrate micronized e hoʻonui me ka koina meaʻai.

Hoʻopili paʻa nā waikawa Fenofibroic a ʻoi aku ka 99% e hoʻopili ai i ka albumin plasma.

Metabolism a me ka hoʻopā ʻana

Ma hope o ka lawelawe waha, ua hoʻopili koke ʻia ka fenofibrate e nā esterases i ka acid fenofibroic, ʻo ia kāna hana metabolite koʻikoʻi. ʻAʻole ʻike ʻia ka Fenofibrate ma ka plasma. ʻAʻole o Fenofibrate kahi papa i ka CYP3A4, ʻaʻole i komo i ka metabolism microsomal i loko o ka puʻuwai.

Hoʻopau ka Fenofibrate i ka nui o ka urine i ke ʻano o ka waikawa fenofibroic a me nā konuate glucuronide. I loko o 6 mau lā, ua hoʻopau loa ka fenofibrate. I nā maʻi maʻi maʻi, ʻaʻole e loli ka nui o ka hoʻopiha o ka waikena fenofibroic. ʻO ka hapalua hapalua o nā wa asuma fenofibroic (T1 / 2) he mau hola 20. Ke hōʻike ʻole ʻia ka hemodialysis. Ua hōʻike nā haʻawina Kinetic ʻaʻole i hōʻiliʻili ʻo fenofibrate ma hope o hoʻokahi pākahi a me ka hoʻohana mau ʻana.

ʻO kahi ʻaihue hypolipidemic mai ka hui o kahi'ōnaehana o ka waikawa fibroic.Hiki i Fenofibrate ke hoʻololi i ka ʻike lipid ma ke kino o ke kanaka ma o ka hoʻōla ʻana o nā ʻĀina (PPAR-α receptors (alpha receptors e hoʻihoʻi ʻia e ka peroxisome proliferator).

Hoʻonui ka Fenofibrate i ka lipolysis plasma a me ka hoʻopuka ʻana i nā lipoproteins atherogen me ka ʻike nui o ka triglycerides ma o ka hoʻoulu ʻana i nā receptors PPAR-α, lipoprotein lipase a hōʻemi i ka hoʻohuihui o ka apoprotein C-III (apo C-III). ʻO nā hopena i hōʻike ʻia i luna ke alakaʻi i ka hapa o ka lipoprotein haʻahaʻa haʻahaʻa (LDL) a me ka lipoprotein density low (VLDL), kahi me nā apoprotein B (apo B), a me ka hoʻonui ʻana i ka hapa hapa o ka lipoprotein density haʻahaʻa (HDL), e loaʻa ana ka apoprotein A-I ( apo A-I) a me apoprotein A-II (apo A-II). Eia kekahi, ma muli o ka hoʻoponopono ʻana o ka synthesis a me ka catabolism disorder o VLDL, hoʻonui ka fenofibrate i ka hoʻomaʻemaʻe ʻana o LDL a hoʻēmi i nā kiko o nā hapa liʻiliʻi a me ka palu o ka LDL (hoʻonui i kēia LDL e nānā i nā mea maʻi me ka lipotype lipher atherogen a pili pū me kahi hiki i ka nui o ka hopena o ka maʻi naʻau coronary-IHD).

I nā haʻawina loiloi, ua hōʻike ʻia ka hoʻokaʻawale ʻana o ka hoʻohana ʻana i ka fenofibrate i ka pae o ka kolamu o ka kolamu (Ch) ma ka 20-25% a me ka triglycerides e ka 40-55% me ka piʻi o ka pae o ka HDL-C ma ka 10-30%. I ka poʻe maʻi me ka hypercholesterolemia, kahi e hōʻemi ʻia ai ke kiʻekiʻe o Chs-LDL e ka 20-35%, ka hoʻohana ʻana o ka fenofibrate i ka hōʻemi i nā kāwili: ʻo ka huina Chs / Chs-HDL, Chs-LDL / Chs-HDL a me apo B / apo A-I, he mau mea hōʻailona o ka atherogenic. Hoʻopilikia.

Ke noʻonoʻo nei i ka hopena o ka fenofibrate ma ka pae o LDL-C a me ka triglycerides, hoʻohana ʻia ka lāʻau lapaʻau i nā mea maʻi me ka hypercholesterolemia, hui pū ʻole ʻia a ʻaʻole pū ʻia e hypertriglyceridemia, me ka hyperlipoproteinemia lua, no ka laʻana, me ka type 2 diabetes mellitus.

ʻAʻohe manaʻo e hiki i nā fibrates ke hōʻemi i ka ulu ʻana o ka maʻi naʻau coronary, akā ʻaʻohe hōʻailona no ka hoʻemi ʻana o ka nui o ka make ma ka maʻamau a i ʻole ke kaulike ʻana o ka maʻi cardiovascular.

I ka wā o ka mālama ʻana me ka fenofibrate, ka nui o nā huna maʻa o XC (tendon a me tubanthous xanthomas) hiki ke hoʻohaʻahaʻa loa a emi loa. I nā maʻi me nā kiʻekiʻe o ka fibrinogen i mālama ʻia me ka fenofibrate, ua ʻike ʻia kahi emi nui i loko o kēia hōkuhi, a me nā mea maʻi me nā kiʻekiʻe o ka lipoproteins. I ka mālamaʻana i ka fenofibrate, ua nānā ʻia kahi emi o ka neʻe ʻana o ka protein C-reactive a me nā mākaʻi ʻē aʻe o ka mumū.

No ka poʻe maʻi me ka dyslipidemia a me ka hyperuricemia, ʻoi aku ka maikaʻi o ka mea i loaʻa i ka fenofibrate ka hopena uricosuric, kahi e hiki ai i ka emi o ka hoʻoweliweli ʻana o ka waikina uric ma kahi o 25%.

I nā haʻawina hōʻike maʻi a ma nā hoʻokolohua holoholona, ​​ua hōʻike ʻia ka fenofibrate e hōʻemi i ka hoʻohui o platelet i kumu ʻia e ka adenosine diphosphate, acid arachidonic, a me ka epinephrine.

Hoʻopili i nā lāʻau lapaʻau

ʻAʻole kōkua ʻia nā anticoagulants waha i ka manawa like me Lipantil 200M. Hoʻonui ka Fenofibrate i ka hopena o nā anticoagulants o ka waha a hoʻonui i ka hopena o ke kahe. I ka hoʻomaka o ka hoʻōla me ka fenofibrate, ke kahakaha nei e hōʻemi i ka nui o nā anticoagulants e pili ana i kahi hapakolu, ukali ʻia e kahi koho lohi o ka pauʻa. Kuhi ʻia ke koho ʻana e mālama ʻia ma lalo o ka kaohi o ka pae o ka MHO (ratio maʻamau maʻamau maʻamau).

Cyclosporin. Ua hōʻike ʻia he mau hihia koʻikoʻi o ka hoʻohuli o ka hana i ka wā hana i ka wā mālama me ka fenofibrate a me ka cyclosporine. No laila, he mea pono e nānā i ka kūlana o ka hana a ka renal i kēlā me nā mea maʻi a kāpae iā Lipantil 200M inā he hoʻololi koʻikoʻi i nā ʻāpana laboratorium.

Co-A reductase inhibitors a me nā fibrates ʻē aʻe. Ke lawe nei i ka fenofibrate i ka manawa like me ka HMG-CoA reductase inhibitors a me nā fibrates ʻē aʻe, e hoʻonui ʻia ka hopena o ka hopena hōʻona ma ke kinipona o nā iwi. Pono e hoʻohana pono i nā lāʻau lapaʻau o kēia hui pū me Lipantil 200M me ka akahele, pono nā mea maʻi e nānā pono no nā hōʻailona o ka hōʻiliʻili o ka naʻau.

ʻO nā Glitazones. Aia nā hōʻike no kahi hōʻemi o kahi paradoxical i ka hōʻemi o ka HDL cholesterol i ka wā e lawe ana i ka fenofibrate i hoʻohui pū me kahi lāʻau mai ka pūʻulu glitazone. No laila, ʻoi aku ia e nānā i ke kiʻekiʻe o ka HDL cholesterol me ka hoʻohana pū ʻana me nā lāʻau lapaʻau a i ʻole ka hoʻopau ʻia ʻana o kekahi o lākou, me ka haʻahaʻa o ka HDL cholesterol.

Enzymes Cytochrome P450. I loko o nā haʻawina vitro o nā mikrosome ati o ke kanaka i hōʻike i ka fenofibrate a me ka acid fenofibroic, ʻaʻole nā ​​mea i pale aku o ka isoenzymes CYP3A4, CYP2D6, CYP2E1 a i ʻole CYP1A2. I nā hōʻuluʻulu therapeutic, ʻo kēia mau pūhui nāwaliwali nā hōʻemi o ka isoenzymes CYP2C19 a me CYP2A6 a i nāwaliwali a i ʻole e hōʻemi i ka hoʻoneʻeʻana o CYP2C9.

ʻO ka poʻe maʻi e lawe ana i nā lāʻau lapaʻau me kahi puʻupuʻu therapeutic pōkā i ka manawa like me ka fenofibrate, i loko o ka metabolism kahi o nā enzyme CYP2C19, CYP2A6 a, ʻoi paha, CYP2C9 e komo, pono e nānā pono. Inā kūpono, e hōʻike ʻia kahi hoʻoponopono ʻana o kēia mau lāʻau.